These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33095855)

  • 21. A novel high throughput assay to quantify Epstein-Barr virus neutralizing antibody activity against B-cell and epithelial cell infections for vaccine and therapeutic developments.
    Li F; Freed D; Heidecker G; Galli J; Durr E; Wang D
    Vaccine; 2022 Jun; 40(26):3638-3646. PubMed ID: 35577627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
    Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
    J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine.
    Baroncelli S; Galluzzo CM; Liotta G; Andreotti M; Orlando S; Ciccacci F; Mphwere R; Luhanga R; Sagno JB; Amici R; Marazzi MC; Giuliano M
    AIDS Res Ther; 2021 Aug; 18(1):48. PubMed ID: 34348748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus.
    Zhong L; Krummenacher C; Zhang W; Hong J; Feng Q; Zhao Q; Chen Y; Zeng MS; Zeng YX; Xu M; Zhang X
    Virol J; 2022 Nov; 19(1):196. PubMed ID: 36424667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
    Chen WH; Kim J; Bu W; Board NL; Tsybovsky Y; Wang Y; Hostal A; Andrews SF; Gillespie RA; Choe M; Stephens T; Yang ES; Pegu A; Peterson CE; Fisher BE; Mascola JR; Pittaluga S; McDermott AB; Kanekiyo M; Joyce MG; Cohen JI
    Immunity; 2022 Nov; 55(11):2135-2148.e6. PubMed ID: 36306784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
    Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
    Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus gp350-specific antibody titers and antibody-dependent cellular cytotoxic effector function in different groups of patients: a study using cloned gp350-expressing transfected human T cell targets.
    Khyatti M; Stefanescu I; Blagdon M; Menezes J
    J Infect Dis; 1994 Dec; 170(6):1439-47. PubMed ID: 7995983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.
    Sashihara J; Burbelo PD; Savoldo B; Pierson TC; Cohen JI
    Virology; 2009 Sep; 391(2):249-56. PubMed ID: 19584018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal HIV Infection as a Risk Factor for Primary Epstein-Barr Virus Infection in Kenyan Infants.
    Samayoa-Reyes G; Ogolla SO; Daud II; Jackson C; Sabourin KR; Dent A; Rochford R
    Front Oncol; 2021; 11():805145. PubMed ID: 35096607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus.
    Zhu QY; Shan S; Yu J; Peng SY; Sun C; Zuo Y; Zhong LY; Yan SM; Zhang X; Yang Z; Peng YJ; Shi X; Cao SM; Wang X; Zeng MS; Zhang L
    Nat Commun; 2021 Nov; 12(1):6624. PubMed ID: 34785638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV.
    Kim J; Bu W; Mine S; Tariq Z; Nguyen H; Wang Y; Tolman C; Mond J; Cohen JI
    Virology; 2021 Sep; 561():80-86. PubMed ID: 34171765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants.
    Holder B; Miles DJ; Kaye S; Crozier S; Mohammed NI; Duah NO; Roberts E; Ojuola O; Palmero MS; Touray ES; Waight P; Cotten M; Rowland-Jones S; van der Sande M; Whittle H
    PLoS One; 2010 Nov; 5(11):e14013. PubMed ID: 21103338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment.
    Condon LM; Cederberg LE; Rabinovitch MD; Liebo RV; Go JC; Delaney AS; Schmeling DO; Thomas W; Balfour HH
    Clin Infect Dis; 2014 Aug; 59(4):501-8. PubMed ID: 24820696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
    Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
    J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
    Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
    J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
    Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
    Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
    Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
    J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.
    Bu W; Hayes GM; Liu H; Gemmell L; Schmeling DO; Radecki P; Aguilar F; Burbelo PD; Woo J; Balfour HH; Cohen JI
    Clin Vaccine Immunol; 2016 Apr; 23(4):363-9. PubMed ID: 26888186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
    Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
    Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.